Eisai Presents New LEQEMBI® (lecanemab-irmb)
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients...
Source: globenewswire.com
Page 2 - Dose Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dose Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dose Management Today - Breaking & Trending Today
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease (CTAD) Conference - Biogen (NASDAQ:BIIB)
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical Improvement At 18
Source: benzinga.com
LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023
Recognized in the Medical Care Category NUTLEY, N.J., and CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Eisai Inc. and Biogen Inc. are honored to announce today that TIME has selected LEQEMBI® ...
Source: marketscreener.com
EISAI TO PRESENT NEW DATA FROM LEQEMBI® (LECANEMAB-IRMB) PHASE 3 CLARITY AD STUDY AND OTHER ALZHEIMER'S DISEASE PIPELINE RESEARCH AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Update on LEQEMBI Investigational Subcutaneous Formulation
Source: channel3000.com
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan - Biogen (NASDAQ:BIIB)
TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:
Source: benzinga.com